Angewandte Chemie · 2020 · 23 citations · 84 references
MedicineMolecular BiologyOncologyMolecular DiagnosticsMolecular OncologyPrecision OncologyAntibody DiscoveryCancer BiomarkersCancer Molecular DiagnosticsLigand BindingTargeting LigandsAptamer RecognitionAptamer-based ProbesAptamersCell-selexChemical ModificationImmobilized LigandsRapid Molecular DiagnosticsSelex
Abstract The advent of SELEX (systematic evolution of ligands by exponential enrichment) technology has shown the ability to evolve artificial ligands with affinity and specificity able to meet growing clinical demand for probes that can, for example, distinguish between the target leukemia cells and other cancer cells within the matrix of heterogeneity, which characterizes cancer cells. Though antibodies are the conventional and ideal choice as a molecular recognition tool for many applications, aptamers complement the use of antibodies due to many unique advantages, such as small size, low cost, and facile chemical modification. This Minireview will focus on the novel applications of aptamers and SELEX, as well as opportunities to develop molecular tools able to meet future clinical needs in biomedicine.
84
In vitro selection of RNA molecules that bind specific ligands
Andrew D. Ellington, Jack W. Szostak · Nature · 1990 · 9.7K citations
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Larry Gold, Deborah Ayers, Jennifer Bertino et al. · PLoS ONE · 2010 · 1.7K citations · Full text
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
Suping Li, Qiao Jiang, Shaoli Liu et al. · Nature Biotechnology · 2018 · 1.5K citations